AI-generated analysis. Always verify with the original filing.
Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel antimicrobial therapeutics, specifically the Bisphosphocin class of compounds, to address antimicrobial resistance (AMR). The company's lead product candidate, Nu-3, is a topical gel for treating infected diabetic foot ulcers (iDFU) and has completed Phase 1/2a trials. The company has not generated any revenue and reported a net loss of $3.1 million for the nine months ended September 30, 2025, with an accumulated deficit of $52.6 million. This filing is an S-1/A registration statement for a direct listing on the Nasdaq Capital Market under the symbol 'LABT'. The registration covers the resale of 4,689,177 shares of common stock by existing stockholders, representing 33.64% of outstanding shares. The company will not receive proceeds from these sales. Concurrently, the company is conducting a private placement of Series C Preferred Stock for $7.5 million to fund operations. The company faces substantial doubt about its ability to continue as a going concern without additional financing.
Offering Amount
$20.0M
Shares Offered
125,000,000
Price Range
$2.13 – $5.92
Shares Offered
4,689,177
Share Type
Common Stock
Exchange
Nasdaq Capital Market
Ticker
LABT
Use of Proceeds: The Company will not receive any proceeds from the sale of shares by the Registered Stockholders.
A clinical-stage biopharmaceutical company focused on the discovery and development of novel antimicrobial therapeutics, specifically the Bisphosphocin class, to address antimicrobial resistance.